Key result
Semaglutide modulates proinflammatory epicardial fat markers FABP4 and sPLA2, demonstrating paracrine effects on atrial cardiomyocytes.
Why the study?
Inflamed epicardial fat accumulation is a cardiovascular risk factor, and GLP-1 receptor agonists reduce epicardial fat thickness, but semaglutide's effects on proinflammatory epicardial adipogenesis and paracrine actions on cardiomyocytes needed demonstration.
Does semaglutide modulate proinflammatory epicardial adipogenesis and exert paracrine effects on atrial cardiomyocytes?
Does semaglutide modulate proinflammatory epicardial adipogenesis and exert paracrine effects on atrial cardiomyocytes?
Semaglutide reduces proinflammatory markers in epicardial fat with beneficial paracrine effects on atrial cardiomyocytes, providing a potential mechanistic basis for its cardiovascular benefits.
May support mechanistic basis for semaglutide CV benefits; hypothesis-generating and should not yet change practice.
Inflamed epicardial fat (EAT) accumulation around the myocardium and coronaries is a risk factor for cardiovascular disease. Glucagon-like peptide receptor-agonists 1 improves the insulin response and reduces EAT thickness. We aimed to demonstrate the effect of semaglutide on proinflammatory epicardial adipogenesis with paracrine effects on cardiomyocytes. Biopsies or isolated stromal cells from subcutaneous adipose tissue and EAT of 67 patients undergoing open-heart surgery were studied by real-time quantitative polymerase chain reaction, proteomics, and metabolic assays. Adipogenesis assay and paracrine effect over atrial cardiomyocytes determined that semaglutide treatment modulates proinflammatory adiposity markers FABP4 and sPLA2 in epicardial adipogenesis with a paracrine effect in atrial cardiomyocytes.
No takes yet. Share an insight, caveat, or question.
Basdas et al. (2025) studied Cardiovascular disease (patients undergoing open-heart surgery) (n=67). Semaglutide was evaluated on Modulation of proinflammatory adiposity markers FABP4 and sPLA2 in epicardial adipogenesis. Semaglutide treatment of epicardial fat biopsies from 67 patients modulated proinflammatory adiposity markers FABP4 and sPLA2, demonstrating a paracrine effect on atrial cardiomyocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: